Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2022 | $74.00 | Neutral | H.C. Wainwright |
| 8/4/2022 | Outperform → Mkt Perform | SVB Leerink | |
| 6/14/2022 | $139.00 | Buy | UBS |
| 6/6/2022 | $95.00 | Mkt Perform | SVB Leerink |
| 5/23/2022 | $95.00 | Mkt Perform | SVB Leerink |
| 3/15/2022 | $140.00 | Outperform | Oppenheimer |
| 3/2/2022 | $135.00 → $140.00 | Overweight | Morgan Stanley |
| 12/8/2021 | $137.00 | Overweight | Wells Fargo |
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
15-12G - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
H.C. Wainwright initiated coverage of Horizon Pharma with a rating of Neutral and set a new price target of $74.00
SVB Leerink downgraded Horizon Pharma from Outperform to Mkt Perform
UBS initiated coverage of Horizon Pharma with a rating of Buy and set a new price target of $139.00